HC Wainwright Has Optimistic Outlook of PVLA FY2027 Earnings

Palvella Therapeutics, Inc. (NASDAQ:PVLA) – HC Wainwright boosted their FY2027 earnings estimates for shares of Palvella Therapeutics in a research note issued to investors on Tuesday, February 24th. HC Wainwright analyst A. Fein now forecasts that the company will post earnings of ($3.43) per share for the year, up from their prior forecast of ($3.65). HC Wainwright currently has a “Buy” rating and a $255.00 target price on the stock. The consensus estimate for Palvella Therapeutics’ current full-year earnings is ($3.69) per share. HC Wainwright also issued estimates for Palvella Therapeutics’ FY2028 earnings at ($1.84) EPS, FY2029 earnings at $2.19 EPS and FY2030 earnings at $11.56 EPS.

Several other equities analysts also recently weighed in on PVLA. Stifel Nicolaus set a $250.00 target price on Palvella Therapeutics in a research report on Tuesday. BTIG Research increased their target price on shares of Palvella Therapeutics from $192.00 to $215.00 and gave the company a “buy” rating in a research note on Wednesday. TD Cowen restated a “buy” rating on shares of Palvella Therapeutics in a report on Monday, February 2nd. Raymond James Financial reiterated a “strong-buy” rating and set a $193.00 price target on shares of Palvella Therapeutics in a report on Tuesday, December 16th. Finally, Cantor Fitzgerald raised their price objective on shares of Palvella Therapeutics from $120.00 to $200.00 and gave the stock an “overweight” rating in a research note on Thursday, November 6th. Two equities research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Palvella Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $176.44.

Palvella Therapeutics Trading Up 6.8%

PVLA opened at $128.60 on Thursday. Palvella Therapeutics has a 12 month low of $18.23 and a 12 month high of $129.32. The stock has a 50-day moving average of $92.78 and a 200 day moving average of $78.86. The firm has a market cap of $1.52 billion, a P/E ratio of -48.90 and a beta of -0.16.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. Millennium Management LLC purchased a new stake in shares of Palvella Therapeutics in the 1st quarter worth approximately $7,553,000. Goldman Sachs Group Inc. bought a new stake in Palvella Therapeutics during the 1st quarter valued at $533,000. Geode Capital Management LLC increased its holdings in shares of Palvella Therapeutics by 84.7% in the 2nd quarter. Geode Capital Management LLC now owns 173,986 shares of the company’s stock valued at $3,923,000 after acquiring an additional 79,787 shares during the period. Police & Firemen s Retirement System of New Jersey bought a new stake in Palvella Therapeutics during the second quarter valued at about $37,000. Finally, JPMorgan Chase & Co. raised its holdings in Palvella Therapeutics by 108,066.7% in the second quarter. JPMorgan Chase & Co. now owns 3,245 shares of the company’s stock worth $73,000 after purchasing an additional 3,242 shares in the last quarter. Hedge funds and other institutional investors own 40.11% of the company’s stock.

Insider Buying and Selling at Palvella Therapeutics

In other news, COO Kathleen Goin sold 4,302 shares of the stock in a transaction on Wednesday, January 21st. The stock was sold at an average price of $97.63, for a total transaction of $420,004.26. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 20.50% of the company’s stock.

Key Stories Impacting Palvella Therapeutics

Here are the key news stories impacting Palvella Therapeutics this week:

• Positive Sentiment: Company announced positive topline Phase 3 SELVA results for lead asset QTORIN™ 3.9% rapamycin, a material clinical win that supports future approvals and revenue potential. Palvella Therapeutics Announces Positive Topline Results
• Positive Sentiment: Multiple brokerages raised price targets and reiterated buy/outperform ratings (H.C. Wainwright to $255, Mizuho to $250, BTIG to $215, Chardan to $210), reflecting higher revenue/profit forecasts and boosting investor confidence. H.C. Wainwright price target raise
• Positive Sentiment: HC Wainwright materially raised multi-year EPS forecasts (notably FY2030 to $11.56), signaling expectations of strong long-term cash generation if programs succeed — a catalyst for higher valuation models. HC Wainwright estimates
• Positive Sentiment: Institutional buying and multiple recent analyst upgrades increase demand-side support and reinforce the bullish narrative around a successful Phase 3. (See aggregated analyst/hedge fund activity in public reports.) QuiverQuant summary
• Neutral Sentiment: Palvella priced an upsized public offering of 1.6M shares at $125 to raise ~ $200M (with a 30-day overallotment), which strengthens the cash runway to advance QTORIN programs but will dilute existing shareholders when closed. Expected close ~Feb 27, 2026. GlobeNewswire offering release
• Neutral Sentiment: Short interest rose ~22% in February to ~1.67M shares (~17.8% of float; ~5.5 days to cover). Elevated shorts increase volatility risk and could amplify moves in either direction. (Data from short interest filings summary.)
• Negative Sentiment: Insider selling activity has been notable (multiple recent open-market sales), which investors sometimes view as a negative signal on share timing despite company cash needs. QuiverQuant insider summary

About Palvella Therapeutics

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.